Galindo SRM, Martínez VE, Frati MAC

Language: Spanish
References: 26
Page: 347-354
PDF size: 77.55 Kb.

ABSTRACT

Background: The five available proton pump inhibitors for the treatment of gastroesophageal reflux disease have different alleged benefits and prices.
Objective: To determine the proton pump inhibitors with the best cost/effectiveness index in order to orient its reasonable prescription.
Material and methods: A cost/effectiveness analysis of the proton pump inhibitors was performed using omeprazole 20 mg (innovator and generic), pantoprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg and esomeprazole 40 mg. This, using published data on effectiveness in gastroesophageal reflux disease and according to the prices in the Mexican market during the year 2004.
Results: Esomeprazole was more effective than the other proton pump inhibitors: esophageal lesion healing rate was 74.2 and 88.8% at four and eight weeks with esomeprazole, and 64.4 to 66.4% and 80.6 to 83% with the other proton pump inhibitors in the same period. Omeprazole was the cheapest drug in private pharmacies and in public health institutions. Furthermore, it had the best cost/effectiveness ratio. The cost per cured patient (Mexican pesos) with eight weeks treatment in private medicine was of: $389 with generic omeprazole; $953 with innovator omeprazole; $1,576 with esomeprazole; $1,789 with rabeprazole, $1,831 with pantoprazole, and $2,397 with lansoprazole. In public health institutions the cost was of: $32 with omeprazole; $521 with pantoprazole; $1,288 with esomeprazole, and $1,424 with rabeprazole.
Conclusions: All the proton pump inhibitors are useful for the gastroesophageal reflux treatment. Effectiveness was higher with esomeprazole, but omeprazole had the best cost/effectiveness ratio.

REFERENCES

1. Dirección General de Información y Evaluación del Desempeño. Subsecretaría de Innovación y Calidad. Secretaría de Salud. Salud: México 2002. Información para la rendición de cuentas.

2. Mossiales E. El impacto sobre los medicamentos de la contención del gasto y las reformas en la asistencia sanitaria. En: Lobo F, Velásquez G. Los medicamentos ante las nuevas realidades económicas. Madrid: Civitas, 1997;pp:109-49.

3. García-González MA. La guía de la buena prescripción. Guadalajara, 2003.

4. Díaz-López JA, García-González MA. Conceptos básicos en farmacoeconomía. Guadalajara, 2001.

5. Brogden RN, Heel RC, Speight TM, Avery GS. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs 1978;15(2):93-131.

6. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996;276(12):983-8.

7. Sugiyama T, Asaka M. Eradication effect of lansoprazole-based triple therapy against H. pylori. Nippon Rinsho 2004;62(3):483-8.

8. Beck J. Efficacy of esomeprazole in patients with acid-peptic disorders. Gastroenterol Nurs 2004;27(2):44-49.

9. Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 2004;5(1):137-49.

10. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroentrol Hepatol 2004;16(1):89-99.

11. Edwards S, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1729-36.

12. Plumb J, Edwards S. Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis. J Med Econ 2002;5:25-38.

13. Klok RM, Postma JM, Van Hout BA, Brouwers JRBJ. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003;17:1237-45.

14. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis. Pharmacoeconomics 2002;20(4):267-77.

15. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112(6): 1798-810.

16. WHO. How to develop and implement a national drug policy. Geneva, WHO 2001.

17. Carlsson R, Dent J, Watts R, et al. Gastroesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-29.

18. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastroesophageal reflux disease: a double-blind comparison of omeprazol and cisapride. Aliment Pharmacol Ther 1997;11:765-73.

19. Fass R, Fennerty MB, Vakil NB. Nonerosive reflux disease: current concept and dilemmas. Am J Gastroenterol 2001;96:303-14.

20. Kahrilos PJ. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98(Suppl 3):S15-S23.

21. Kahrilos PJ, Miner P, Johanson J, et al. Efficacy of rabeprazole in endoscopically negative GERD patients with frequent moderate to severe heartburn symptoms. Gastroenterology 2002;122(4):A1280.

22. Johanson J, Miner P, Orr W, et al. Efficacy of rabeprazole for heartburn and associated symptoms in endoscopically negative GERD. Gastroenterology 2002;122(4):A1294.

23. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20.

24. Kale-Pradhan P, Landry HK, Sypula WT. Esomeprazole for acid peptic disorders. Ann Pharmacother 2002;36:655-63.

25. Velázquez-Carvajal A, Azcona-Llanezca T. Calidad de los medicamentos genéricos. En: Díez Rodrigálvarez. Genéricos. Claves para su conocimiento y comprensión. Madrid: Editores Médicos, 1999.

26. González-Luna MS. Los medicamentos genéricos: un acierto patente. Innovación y libre competencia en la industria farmacéutica nacional. México: Porrúa, 2004.